observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021. Study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients; * to identify the factors that affect the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment; * to provide a platform for future research projects; * Description of the various therapies that have occurred over time, duration of treatment, causes of interruption of treatment, responses; * Description of the adverse events / safety of the various therapies for lymphoma and lymphoproliferative syndromes; * Patient survival. Descriptive analyses will be conducted by tabulating frequency distributions and percentages and mean and median values, standard deviations, quartiles and extreme values for continuous variables. Progression-free survival, disease-free survival and overall survival will be examined using Kaplan-Meier point estimates
Study Type
OBSERVATIONAL
Enrollment
5,500
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Bologna, Italy
RECRUITINGIncidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021
Incidence and prevalence
Time frame: through study completion, an average of 6 years
Overall Survival (OS)
Overall Survival (OS)
Time frame: through study completion, an average of 6 years
event free survival (EFS)
event free survival (EFS)
Time frame: through study completion, an average of 6 years
Lymphoma specific survival (LSS)
Lymphoma specific survival (LSS)
Time frame: through study completion, an average of 6 years
Progression Free Survival (PFS)
Progression Free Survival (PFS)
Time frame: through study completion, an average of 6 years
Net survival (5 years)
Net survival
Time frame: through study completion, an average of 6 years
Response rate (5 years)
Response rate
Time frame: through study completion, an average of 6 years
Duration of Response (DoR)
Duration of Response (DoR)
Time frame: through study completion, an average of 6 years
time to next anti-lymphoma treatment (TTNLT)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
time to next anti-lymphoma treatment (TTNLT)
Time frame: through study completion, an average of 6 years
Duration of survival after progression
Duration of survival after progression
Time frame: through study completion, an average of 6 years
lymphoma transformation frequency
lymphoma transformation frequency
Time frame: through study completion, an average of 6 years
Frequency of secondary neoplasy
Frequency of secondary neoplasy
Time frame: through study completion, an average of 6 years
frequency of other chronic diseases
frequency of other chronic diseases
Time frame: through study completion, an average of 6 years